Search bioRxiv⌕ Search

Biology subjects

Weight, A. E.

Publications and source records attributed to Weight, A. E..

2 recordsLinked to original sources

The La Crosse virus M segment determines virus isolate cell-to-cell spread and virulence

La Crosse virus (LACV) is an orthobunyavirus spread by mosquitoes in North America and can cause severe neurological disease. Despite this burden, there is a lack of LACV antiviral treatments as our fundamental understanding of how LACV spreads and causes disease remains incomplete. To investigate LACV biology, we took advantage of two genetically similar LACV lineage I isolates (LACV1960 and LACV1978) where we found that LACV1960 infects and replicates at a higher rate than LACV1978, while LACV1978 exhibits enhanced cell-cell spread and in vivo virulence and dissemination. To investigate the genomic determinants behind these phenotypes, we generated reassortants between each isolate. We found that each genomic segment contributed to LACV pathogenesis with the M segment as a dominant determinant for LACV pathogenesis in vivo and plaque size and replication in vitro. To address which M segment protein contributes to plaque size and infectivity, we generated M segment chimeric viruses using a LACV1978 background and swapping in regions of the LACV1960 M segment. We found that the Gc head domain determined plaque size and infectivity, with the LACV1960 Gc head chimera producing small plaques but having increased infectivity over the wild-type LACV1978. Finally, using natural LACV lineage isolates, we showed that plaque size is variable across and within lineages suggesting changes in the M segment may impact LACV in nature. In future studies, we will continue to investigate the mechanisms behind how cell-to-cell spread influences dissemination to better understand how LACV genome segments affect spread, infectivity, virulence, and viral fitness.

microbiology↗

A bivalent self-amplifying RNA vaccine against yellow fever and Zika viruses

IntroductionYellow fever (YFV) and Zika (ZIKV) viruses cause significant morbidity and mortality, despite the existence of an approved YFV vaccine and the development of multiple ZIKV vaccine candidates to date. New technologies may improve access to vaccines against these pathogens. We previously described a nanostructured lipid carrier (NLC)-delivered self-amplifying RNA (saRNA) vaccine platform with excellent thermostability and immunogenicity, appropriate for prevention of tropical infectious diseases. MethodsYFV and ZIKV prM-E antigen-expressing saRNA constructs were created using a TC-83 strain Venezuelan equine encephalitis virus-based replicon and complexed with NLC by simple mixing. Monovalent and bivalent vaccine formulations were injected intramuscularly into C57BL/6 mice and Syrian golden hamsters, and the magnitude, durability, and protective efficacy of the resulting immune responses were then characterized. Results and discussionMonovalent vaccines established durable neutralizing antibody responses to their respective flaviviral targets, with little evidence of cross-neutralization. Both vaccines additionally elicited robust antigen-reactive CD4+ and CD8+ T cell populations. Notably, humoral responses to YFV saRNA-NLC vaccination were comparable to those in YF-17D-vaccinated animals. Bivalent formulations established humoral and cellular responses against both viral targets, commensurate to those established by monovalent vaccines, without evidence of saRNA interference or immune competition. Finally, both monovalent and bivalent vaccines completely protected mice and hamsters against lethal ZIKV and YFV challenge. We present a bivalent saRNA-NLC vaccine against YFV and ZIKV capable of inducing robust and efficacious neutralizing antibody and cellular immune responses against both viruses. These data support the development of other multivalent saRNA-based vaccines against infectious diseases.

immunology↗